Company Overview
About CUTISS
CUTISS is a Swiss clinical-stage biotechnology company founded in 2017 as a spin-off from the University Children's Hospital Zurich, focused on developing personalized bioengineered skin grafts for patients with large skin defects caused by severe burns, rare congenital skin diseases, and traumatic wounds. The company's lead product, denovoSkin, is a dermo-epidermal skin graft manufactured by combining a small biopsy of a patient's own skin cells with a proprietary hydrogel scaffold — which is then cultured to grow a full-thickness skin equivalent containing both the dermis (dermal layer) and epidermis (outer layer). Because the graft uses the patient's own cells, it avoids immune rejection without the need for immunosuppression.
Business Model & Competitive Advantage
denovoSkin addresses a critical limitation of current burn and skin defect treatment: split-thickness autografting — the standard of care — requires harvesting skin from an unaffected area of the patient's body (the donor site), which creates additional wounds, limits graft size by available donor skin, and can leave permanent scarring at donor sites. CUTISS's bioengineered approach generates sufficient graft area from a small biopsy, reducing the number of autograft surgeries needed and the associated donor-site morbidity. The company has raised over CHF 30 million in funding from Swiss and European investors and is advancing denovoSkin toward European Medicines Agency (EMA) marketing authorization.
Competitive Landscape 2025–2026
CUTISS operates in the emerging advanced therapy medicinal products (ATMP) sector, alongside companies such as Avita Medical (ReCell), Stratatech, and Integra LifeSciences in the broader wound care market. CUTISS differentiates through its full-thickness dermo-epidermal construct — which more closely resembles natural skin than split-thickness grafts or dermal substitutes alone — and its personalized, cell-based manufacturing process that makes it an autologous therapy with strong safety credentials.
Key Differentiators
Emerging Innovator
CUTISS is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Compare CUTISS with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from CUTISS? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim CUTISS Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention CUTISS vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →